RhumbLine Advisers
TEVA icon

RhumbLine Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

RhumbLine Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.09M Buy
238,823
+2,554
+1% +$85.1K 0.01% 1208
2026
Q1 		$7.12M Sell
236,269
-8,369
-3% -$269K 0.01% 1224
2025
Q4 		$7.64M Sell
244,638
-25,771
-10% -$635K 0.01% 1188
2025
Q3 		$5.46M Sell
270,409
-16,992
-6% -$298K ﹤0.01% 1387
2025
Q2 		$4.82M Buy
287,401
+6,339
+2% +$102K ﹤0.01% 1437
2025
Q1 		$4.32M Buy
281,062
+2,128
+0.8% +$38K ﹤0.01% 1432
2024
Q4 		$6.15M Sell
278,934
-43,150
-13% -$785K 0.01% 1326
2024
Q3 		$5.8M Sell
322,084
-16,571
-5% -$290K 0.01% 1348
2024
Q2 		$5.5M Sell
338,655
-2,396
-0.7% -$36.9K 0.01% 1347
2024
Q1 		$4.81M Buy
341,051
+8,259
+2% +$104K ﹤0.01% 1439
2023
Q4 		$3.47M Buy
332,792
+33,792
+11% +$315K ﹤0.01% 1625
2023
Q3 		$3.05M Buy
299,000
+33,436
+13% +$311K ﹤0.01% 1629
2023
Q2 		$2M Buy
+265,564
New +$2.15M ﹤0.01% 1905
2020
Q3 		– Sell
-13,870
Closed -$171K – 3039
2020
Q2 		$171K Buy
+13,870
New +$157K ﹤0.01% 2826

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

RhumbLine Advisers's TEVA Position: Q2 2026 in Review

RhumbLine Advisers increased its Teva Pharmaceuticals (TEVA) stake by 1.1% in Q2 2026, buying an estimated $85.1K and bringing the position to 238,823 shares worth $8.09M. The position accounts for 0.01% of the portfolio, ranked #1208.

RhumbLine Advisers first reported a position in TEVA in Q2 2020 and has held it in 14 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • RhumbLine Advisers held 238,823 shares of Teva Pharmaceuticals worth $8.09M as of Q2 2026.
  • RhumbLine Advisers bought 2,554 Teva Pharmaceuticals shares in Q2 2026, an estimated $85.1K.
  • Teva Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1208 holding.
  • RhumbLine Advisers first reported a position in Teva Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.